Archive | Clinical Trials

Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma

Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma

Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Relatlimab/Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma

The addition of relatlimab to nivolumab (Opdivo) prolonged benefit beyond initial treatment and first progression and reduced the risk of progression…

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

Adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma…

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials